AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
TORONTO -- Swiss Medica (OTCBB:SWME) is pleased to announce that the randomized double blind clinical trial using the O24(TM) pain relief product on patients suffering from fibromyalgia has been completed and a final report will be issued in January.
The clinical trials, which began October 1st, were recently concluded, according to Dr. Gordon Ko, medical director of the Canadian Centre for Integrative Medicine, who conducted the study. The results are currently being analyzed by the Institute of Clinical Evaluative Studies (ICES) in Toronto. There are 21,000 pages of data to be analyzed on the 150 fibromyalgia patients who were tested with the O24 product and a placebo over an extended period.
At present, there are no medications approved by the U.S. Food and Drug Administration (FDA) for treating fibromyalgia, a common and chronic disorder characterized by widespread muscle pain, fatigue, and multiple tender points.
About Dr. Gordon Ko
Dr. Gordon Ko is an active member of the American Association of Electrodiagnostic Medicine, the Association for Applied Psycho-physiology and Biofeedback and the…
Source: HighBeam Research, Randomized Double Blind Clinical Trial on Swiss Medica's O24 Pain...